GPCR vs. PTCT, ADMA, ZLAB, RNA, OGN, ACLX, SWTX, RARE, AKRO, and ALVO
Should you be buying Structure Therapeutics stock or one of its competitors? The main competitors of Structure Therapeutics include PTC Therapeutics (PTCT), ADMA Biologics (ADMA), Zai Lab (ZLAB), Avidity Biosciences (RNA), Organon & Co. (OGN), Arcellx (ACLX), SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), Akero Therapeutics (AKRO), and Alvotech (ALVO). These companies are all part of the "pharmaceutical products" industry.
Structure Therapeutics vs.
PTC Therapeutics (NASDAQ:PTCT) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, community ranking, institutional ownership, analyst recommendations and media sentiment.
In the previous week, PTC Therapeutics had 5 more articles in the media than Structure Therapeutics. MarketBeat recorded 11 mentions for PTC Therapeutics and 6 mentions for Structure Therapeutics. PTC Therapeutics' average media sentiment score of 1.10 beat Structure Therapeutics' score of 1.01 indicating that PTC Therapeutics is being referred to more favorably in the media.
PTC Therapeutics received 537 more outperform votes than Structure Therapeutics when rated by MarketBeat users. However, 88.57% of users gave Structure Therapeutics an outperform vote while only 61.87% of users gave PTC Therapeutics an outperform vote.
91.8% of Structure Therapeutics shares are owned by institutional investors. 5.5% of PTC Therapeutics shares are owned by company insiders. Comparatively, 9.4% of Structure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Structure Therapeutics has a net margin of 0.00% compared to PTC Therapeutics' net margin of -50.32%. PTC Therapeutics' return on equity of 0.00% beat Structure Therapeutics' return on equity.
PTC Therapeutics presently has a consensus target price of $64.00, suggesting a potential upside of 15.55%. Structure Therapeutics has a consensus target price of $81.29, suggesting a potential upside of 305.42%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Structure Therapeutics is more favorable than PTC Therapeutics.
Structure Therapeutics has lower revenue, but higher earnings than PTC Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.
PTC Therapeutics has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Comparatively, Structure Therapeutics has a beta of -2.37, indicating that its share price is 337% less volatile than the S&P 500.
Summary
Structure Therapeutics beats PTC Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Structure Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Structure Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:GPCR) was last updated on 3/26/2025 by MarketBeat.com Staff
Buy GPCR Stock Free GPCR Stock Alerts